Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined ImmunodeficiencyGlobeNewsWire • 07/27/22
Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom MacroglobulinemiaGlobeNewsWire • 06/22/22
Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T TherapyGlobeNewsWire • 06/13/22
Mustang Bio Posts Encouraging Interim Data From Gene Therapy Trial In ImmunodeficiencyBenzinga • 05/19/22
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107GlobeNewsWire • 05/19/22
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/12/22
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid CongressGlobeNewsWire • 05/12/22
Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual MeetingGlobeNewsWire • 05/03/22
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaGlobeNewsWire • 04/25/22
Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of GlioblastomaGlobeNewsWire • 04/13/22
Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley SecuritiesGlobeNewsWire • 04/04/22
Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/23/22
Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children's Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewsWire • 03/09/22
Mustang Bio Completes a $75 Million Debt Financing with Runway Growth CapitalGlobeNewsWire • 03/08/22
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers SymposiumGlobeNewsWire • 02/15/22
Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact AwardsGlobeNewsWire • 02/08/22
Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted PatientsGlobeNewsWire • 01/24/22
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRGlobeNewsWire • 01/07/22
Mustang Bio to Participate in Three January 2022 Virtual Investor ConferencesGlobeNewsWire • 01/05/22
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaGlobeNewsWire • 12/13/21
